Actively Recruiting

FEMALE
ID04113447

Mitochondrial Donation: An 18 Month Outcome Study.

Led by Newcastle-upon-Tyne Hospitals NHS Trust · Updated on 2025-07-20

25

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

N

Newcastle-upon-Tyne Hospitals NHS Trust

Lead Sponsor

W

Wellcome Trust

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to observe the development of children conceived using Mitochondrial Donation (MD), focusing on fetal and postnatal growth. Researchers will assess neurodevelopmental outcomes at 18 months corrected age using the internationally recognized Bayley-III developmental tool. The study tests the hypothesis that children born through MD IVF techniques show normal neurodevelopment at this age. The study involves monitoring children conceived via Mitochondrial Donation without any treatment intervention, as it is observational. Developmental assessments including the Bayley-III are scheduled at 18 months corrected age. Additional evaluations for normal hearing and vision by audiologists and ophthalmologists are also conducted at the same time point. Participants will be followed from pregnancy through delivery until the child reaches 18 months corrected age. Data on pregnancy, delivery, and child development will be collected and reviewed. The primary outcome is the neurodevelopmental score at 18 months, with secondary outcomes including hearing and vision status. The study provides a comprehensive developmental overview over this period, with no active treatment administered.

CONDITIONS

Brief Title

Mitochondrial Donation: An 18 Month Outcome Study.

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women with confirmed mitochondrial DNA (mtDNA) mutation
  • Suitable to undergo Mitochondrial Donation as a treatment according to HFEA license
  • Provided informed consent before starting Mitochondrial Donation treatment
  • Able and willing to follow the study protocol and evaluation schedule
  • Willing to share pregnancy, delivery, and child development information up to 18 months corrected age
Not Eligible

You will not qualify if you...

  • Declined Mitochondrial Donation treatment in line with HFEA license
  • Unable or unwilling to follow the study protocol and evaluation schedule
  • Unwilling to share pregnancy, delivery, and child development information up to 18 months corrected age

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 18 months

Participants who have undergone Mitochondrial Donation are observed for fetal and postnatal development up to 18 months corrected age.

Visits at key developmental milestones including assessment at 18 months

Trial Site Locations

Total: 1 location

1

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE1 4LP

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

The Utility of pGz in Primary Mitochondrial Disorders

Mitochondrial Myopathies

Actively Recruiting

1 location

Combating the Diagnostic Impasse in Mitochondrial Diseases: ...

Mitochondrial Diseases

Actively Recruiting

2 locations

A Phase II, Single Arm Study to Assess Safety and Efficacy o...

Mitochondrial Diseases

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here